Ono Pharmaceutical Co Ltd., Vanderbilt University and Wuxi Apptec Co. Ltd. have disclosed potassium channel subfamily K member 2 (TREK-1; KCNK2) and or member 10 (TREK-2; KCNK10) blockers reported to be useful for the treatment of depression, schizophrenia, anxiety disorders and bipolar disorder, among others.